Patents by Inventor Colin J. Meyer

Colin J. Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF
    Publication number: 20240115542
    Abstract: The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof.
    Type: Application
    Filed: June 9, 2023
    Publication date: April 11, 2024
    Inventors: Melanie Pei-Heng CHIN, Colin J. MEYER
  • Methods of treating obesity using antioxidant inflammation modulators
    Patent number: 11911395
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 27, 2024
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Colin J. Meyer, Warren Huff
  • Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
    Patent number: 11446313
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 20, 2022
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventor: Colin J. Meyer
  • METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF
    Publication number: 20210161914
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 3, 2021
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventor: Colin J. MEYER
  • Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
    Patent number: 10953020
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 23, 2021
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventor: Colin J. Meyer
  • METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF
    Publication number: 20190350941
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Application
    Filed: November 8, 2017
    Publication date: November 21, 2019
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventor: Colin J. MEYER
  • METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF
    Publication number: 20190091194
    Abstract: The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof.
    Type: Application
    Filed: October 11, 2018
    Publication date: March 28, 2019
    Inventors: Melanie Pei-Heng CHIN, Colin J. MEYER
  • METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS
    Publication number: 20190076443
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
    Type: Application
    Filed: September 13, 2018
    Publication date: March 14, 2019
    Inventors: Colin J. MEYER, Warren HUFF
  • Methods of treating obesity using antioxidant inflammation modulators
    Patent number: 10105372
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 23, 2018
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Colin J. Meyer, Warren Huff
  • SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE
    Publication number: 20180161311
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Application
    Filed: August 14, 2017
    Publication date: June 14, 2018
    Applicants: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael B. SPORN, Karen T. LIBY, Gordon W. GRIBBLE, Tadashi HONDA, Robert M. Kral, Colin J. MEYER
  • Synthetic triterpenoids and methods of use in the treatment of disease
    Patent number: 9757359
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 12, 2017
    Assignees: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Delayed release, oral dosage compositions that contain amorphous CDDO-Me
    Patent number: 9155721
    Abstract: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: October 13, 2015
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Jiang Zhang, Colin J. Meyer
  • METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF
    Publication number: 20150080465
    Abstract: The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof.
    Type: Application
    Filed: August 22, 2014
    Publication date: March 19, 2015
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Melanie Pei-Heng CHIN, Colin J. MEYER
  • DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME
    Publication number: 20140235711
    Abstract: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: Reata Pharmaceuticals, Inc.
    Inventors: Jiang Zhang, Colin J. MEYER
  • Delayed release, oral dosage compositions that contain amorphous CDDO-Me
    Patent number: 8747901
    Abstract: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: June 10, 2014
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Jiang Zhang, Colin J. Meyer
  • Synthetic triterpenoids and methods of use in the treatment of disease
    Patent number: 8455544
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: June 4, 2013
    Assignees: Reata Pharmaecuticals, Inc., Trustees of Dartmouth College
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Synthetic Triterpenoids and Methods of Use in the Treatment of Disease
    Publication number: 20120220652
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Application
    Filed: January 26, 2012
    Publication date: August 30, 2012
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Synthetic triterpenoids and methods of use in the treatment of disease
    Patent number: 8129429
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: March 6, 2012
    Assignees: Reata Pharmaceuticals, Inc., Trustees of Dartmouth College
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME
    Publication number: 20120022156
    Abstract: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.
    Type: Application
    Filed: February 12, 2010
    Publication date: January 26, 2012
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Jiang Zhang, Colin J. Meyer
  • METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS
    Publication number: 20110281955
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
    Type: Application
    Filed: April 12, 2011
    Publication date: November 17, 2011
    Applicant: REATA PHARMACEUTICALS
    Inventors: Colin J. Meyer, Warren Huff